NCT02773979 - PfSPZ Challenge in Healthy Malaria-Naïve Adults in the United States | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 12, 2016

Primary Completion Date

January 22, 2018

Study Completion Date

January 22, 2018

Conditions

Plasmodium Falciparum Infection

Interventions

DRUG

Chloroquine

Administered as 600mg PO, day 1, 300mg PO days 8, 15, 22.

BIOLOGICAL

PfSPZ (NF54) Challenge

Cryopreserved Plasmodium falciparum (Pf) fully infectious sporozoites (SPZ) that have been developed to be used to infect volunteers in controlled human malaria infection (CHMI) to assess the efficacy of antimalarial drugs and vaccines. The PfSPZ (NF54) Challenge contains a laboratory malaria strain isolated from a Dutch traveler to Africa.

OTHER

Placebo

Trial Locations (1)

98101-1466

Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases, Seattle

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH